Overview

Effectiveness of KOS-862 in the Treatment of Lung Cancer

Status:
Terminated
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a potential drug known as KOS-862 or "Epothilone D" has an effect as a 2nd line treatment in non-small cell lung cancer (NSCLC) for patients having failed one prior platinum-containing chemotherapy regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Desoxyepothilone B